Abstract
Neoadjuvant chemotherapy before surgical resection of locally advanced non-small cell lung cancer (NSCLC) has been shown to improve survival compared with surgery alone in several randomized clinical trials. A case report is presented describing the use of paclitaxel and carboplatin in a multimodality regimen for a patient with stage IIIA N2 NSCLC. Studies are ongoing to determine the optimal type and timing of chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 497S-499S |
| Journal | Chest |
| Volume | 116 |
| Issue number | 6 SUPPL. |
| DOIs | |
| State | Published - 1999 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Multimodality therapy
- Neoadjuvant chemotherapy
- Non-small cell lung cancer
- Stage IIIA N2 disease
- Surgery
Fingerprint
Dive into the research topics of 'Clinical presentation of stage IIIA (N2) non-small cell lung cancer: Role of multimodality therapy cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver